WHO ICTRP trial
Homoharringtonine, aclacinomycin, cyctarabine and G-CSF (HCAG) regimen in the…
ChiCTR-IIR-16008809 · Chinese Clinical Trial Registry (ChiCTR) · Recruiting
Key facts
| Trial ID | ChiCTR-IIR-16008809 |
|---|---|
| Public title | Homoharringtonine, aclacinomycin, cyctarabine and G-CSF (HCAG) regimen in the treatment of newly diagnosed elderly acute myeloid leukemia |
| Scientific title | A multi-center, randomized, prospective clinical study of homoharringtonine, aclacinomycin, cyctarabine and G-CSF (HCAG) regimen in the treatment of newly diagnosed elderly acute myeloid leukemia |
| Primary sponsor | Rui Jin hospital affiliated to Shanghai Jiaotong University School of Medicine, Shanghai Institute of Hematology |
| Registry | Chinese Clinical Trial Registry (ChiCTR) |
| Recruitment status | Recruiting |
| Study type | Interventional study |
| Phase | IV (Phase IV study) |
| Countries | China |
| Conditions | Acute myeloid leukemia |
| Interventions | Group A:DA regimen;Group B:HCAG regimen |
| Registration date | Jul 8, 2016 |
| Target size | Group A:202;Group B:202 |
| Registry page | chictr.org.cn |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: